Sawai Group Holdings Co (4887) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2024, was JPY 87,870 million, up 0.5% year-over-year; core operating profit increased 0.8% year-over-year, but results fell short of initial forecasts due to trust restoration activities.

• Profit attributable to owners surged 123.8% year-over-year to JPY 18,901 million, mainly from a gain on the sale of the U.S. business.

• The U.S. business was fully divested in April 2024, resulting in a one-time gain and a shift to a single-segment structure focused on Japan.

• The company is executing a new medium-term plan, emphasizing growth in generics, sustainability, and capital efficiency.

• Unit selling price improved, reflecting efforts to maintain product value in the generic drug business.

Financial highlights

• 1H FY2024 revenue: JPY 87,870 million (+0.5% YoY); core operating profit: JPY 12,575 million (+0.8% YoY); operating profit: JPY 11,755 million (+7.9% YoY); EPS: 146.25 yen (+127.6% YoY).

• Profit attributable to owners rose by JPY 10,457 million to JPY 18,901 million, mainly due to the gain on the U.S. business sale.

• Gross profit margin stable at 31.1%; EBITDA (adjusted) for 1H: JPY 19,085 million (+3.1% YoY).

• Cash and cash equivalents at period end: JPY 49,660 million, up JPY 23,292 million.

• Total assets decreased to JPY 363,748 million from JPY 382,024 million as of March 31, 2024.

Outlook and guidance

• Revised full-year forecast: revenue to increase 4.0% YoY to JPY 183.9 billion, core operating profit up 6.1% YoY.

• 2H FY2024 revenue and core operating profit expected to rise 7.3% and 11.7% YoY, respectively.

• Focus on increasing sales volume, expanding market share, launching new products, and area expansion.

• Ongoing initiatives include new product launches, R&D in formulation technologies, and digital health collaborations.

• The company is focused on stable supply, quality control, and efficiency in production to support growth in the Japanese generics market.